Case report of successful treatment of fibrosing cholestatic hepatitis c with sofosbuvir and ribavirin after liver transplantation

Seminars in Liver Disease

Volumn 34, Issue 1, 2014, Pages 108-112

  Kim, Brian ^a   Trivedi, Anshu ^b   Thung, Swan N ^b   Grewal, Priya ^a  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cholestatic variant of hepatitis C; fibrosing cholestatic hepatitis; hepatitis C virus; liver transplant; ribavirin; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; CYTOKERATIN 7; GAMMA GLUTAMYLTRANSFERASE; MYCOPHENOLIC ACID; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ABDOMINAL DISCOMFORT; ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CASE REPORT; CHOLANGIOGRAPHY; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC GRAFT REJECTION; CHRONIC HEPATITIS; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG USE; FATIGUE; FIBROSING CHOLESTATIC HEPATITIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LEG EDEMA; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOGRAM; MALE; MEDICAL HISTORY; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; MONOTHERAPY; MUSCLE ATROPHY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONAL EXPERIENCE; PORTAL VEIN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSFUSION; TREATMENT DURATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; BIOPSY; CHOLESTASIS, INTRAHEPATIC; COMPLICATION; DRUG COMBINATION; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BIOPSY; CHOLESTASIS, INTRAHEPATIC; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84899633219     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1371084     Document Type: Article

References (17)

1. United Network for Organ Sharing. Transplant trends. Available at: http://www.unos.org/. Accessed November 1, 2013
2. Garcia-Retortillo M., Forns X., Feliu A., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology: 2002; 35 3 680 687 (Pubitemid 34183974)
3. Gane E. J., Portmann B. C., Naoumov N. V., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med: 1996; 334 13 815 820 (Pubitemid 26099603)
4. Berenguer M., Prieto M., Rayón J. M., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology: 2000; 32 4 Pt 1 852 858
5. Cimsit B., Assis D., Caldwell C., et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Transplant Proc: 2011; 43 3 905 908
6. Satapathy S. K., Sclair S., Fiel M. I., Del Rio Martin J., Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res: 2011; 41 4 328 339
7. Narang T. K., Ahrens W., Russo M. W. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl: 2010; 16 11 1228 1235
8. Gopal D. V., Rosen H. R. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl: 2003; 9 4 348 353 (Pubitemid 36443045)
9. Gane E. J., Stedman C. A., Hyland R. H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med: 2013; 368 1 34 44
10. Osinusi A., Meissner E. G., Lee Y. J., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA: 2013; 310 8 804 811
11. Guillouche P., Féray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther: 2011; 33 2 163 174
12. Levitsky J., Fiel M. I., Norvell J. P., et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology: 2012; 142 5 1132 1139, e1
13. Werner C. R., Egetemeyr D. P., Lauer U. M., et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl: 2012; 18 12 1464 1470
14. Al Nahdi N., Ford J. A., Greanya E. D., et al. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol: 2013; 12 1 156 160
15. Garg V., van Heeswijk R., Lee J. E., Alves K., Nadkarni P., Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology: 2011; 54 1 20 27
16. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology: 2012; 56 5 1622 1630
17. Charlton M. R., Gane E. J., Manns M. P., et al. Sofosbuvir and Ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Paper presented at: 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013; Washington, DC